On March 24th, SRF CEO Lisa Fabiny-Kiser will join a panel of innovators, investors, and executives to advance innovation and discuss longevity medicine with FDA regulatory experts.
A significant and vital step forward for the longevity field: the Biomarkers of Aging Consortium. Formed of a diverse group of academic and industry members, the Consortium seeks to “establish reliable biomarkers of aging, particularly for the identification and evaluation of longevity interventions. Learn more…
As partners of the Alliance for Longevity Initiatives (A4LI), SRF is excited to announce the formation of the Longevity Science Caucus to promote initiatives aimed at increasing the healthy average lifespan of all Americans. Read more…
Much of SRF’s research would not be possible without complex scientific equipment. SRF would like to thank its donors for their generous contributions which allow for the purchasing of this equipment, directly enabling research in ending age-related diseases.
The Education Department is hard at work evaluating over 390 student applications and looking forward to hosting presentations and visiting professional fairs in the coming weeks.
Scientists at SENS Research Foundation led by Dr. Tesfahun (Tes) Dessale Admasu have just published their exciting new senolytic strategy to destroy a wider range of senescent cells than has up to now been possible.
One way senescent cells accumulate is when one senescent cell turns a neighboring cell senescent through SASP secretion. SRF scientists have discovered that these secondary senescent cells are resistant to the classic senolytic drugs. However, they have identified a new senolytic strategy that kills these senescent cells.
A supporter asks us if it would accelerate research progress much faster if did most testing in far shorter-lived animals, like the roundworm C. elegans or the fruit fly Drosophila – rather than mice.
A supporter asks us to elaborate on projects other than allotopic expression (AE), that SRF has undertaken that are targeting mitochondrial dysfunction; and how they relate to the original strategy of allotopic expression?
Scientists at SENS Research Foundation led by Dr. Tesfahun (Tes) Dessale Admasu have just published their exciting new senolytic strategy to destroy a wider range of senescent cells than has up to now been possible.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In the final installment of this 5-part series, we look at TAME itself: how it’s structured, how it’s justified, and how the results could impact the push for longevity therapeutics.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 4 of this 5-part series, we look at human data on metformin and neurodegenerative aging diseases.
A supporter asks about the investigative report in Science magazine that suggests the critical study identifying beta-amyloid oligomers as the key actors in Alzheimer’s disease may have been based on fraudulent data.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 3 of this 5-part series, we look at human trials of metformin in prevention and treatment of cancer.
A supporter asks about how the central MitoSENS strategy can be delivered to our cells.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 2 of this 5-part series, we look at some of the human studies on metformin, including a flawed observational study that created the illusion that diabetics on metformin actually live longer than people without diabetes.
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2022 SENS Research Foundation – ALL RIGHTS RESERVED
